Immunomedics (IMMU) : Traders are bullish on Immunomedics (IMMU) as it has outperformed the S&P 500 by a margin of 15.69% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 16.83%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 17.54% in the last 1 week, and is up 23.5% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Immunomedics (NASDAQ:IMMU): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $2.59 and $2.57 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $2.75. The buying momentum continued till the end and the stock did not give up its gains. It closed at $2.68, notching a gain of 3.47% for the day. The total traded volume was 1,431,053 . The stock had closed at $2.59 on the previous day.
The stock has recorded a 20-day Moving Average of 15.59% and the 50-Day Moving Average is 15.46%. Immunomedics Inc. has dropped 16.77% during the last 3-month period . Year-to-Date the stock performance stands at -12.7%.
Immunomedics, Inc. is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. The Companys technologies allow it to create humanized antibodies in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. Its product candidates include 90Y-clivatuzumab tetraxetan. Its radiolabeled antibody is in a Phase III registration trial in patients with advanced pancreatic cancer. Its portfolio of investigational products also includes antibody-drug conjugates (ADCs). Its ADCs consist of sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials for a number of solid tumors and metastatic colorectal cancer (mCRC), respectively. It has other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in clinical and pre-clinical development-stages.